TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: While CTCL is not the predominant focus of this review, it is worth noting the results of the phase III ALCANZA study in patients with CD30-positive relapsed or refractory CTCL, in whom BV was compared to physician’s choice of either oral methotrexate or bexarotene.